MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 717-724

  Leung, Euphemia ^a   Kannan, Nagarajan ^b   Krissansen, Geoffrey W ^c   Findlay, Michael P ^c   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Breast cancer; Clonal selection; HER2; mTOR; PAX2; Rapamycin; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; TAMOXIFEN; TRANSCRIPTION FACTOR PAX2; DNA; S6 KINASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CELL STRAIN MCF 7; CELL VOLUME; CONTROLLED STUDY; DNA CONTENT; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARIECTOMY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL SELECTION; DRUG MECHANISM; DRUG SENSITIVITY; PROTEIN FUNCTION; BREAST TUMOR; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PAX2 TRANSCRIPTION FACTOR; PHENOTYPE; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIROLIMUS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 77953717846     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.9.11432     Document Type: Article

References (28)

1. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008; 44:30-8.
2. Umar A, Kang H, Timmermans AM, Look MP, Meijervan Gelder ME, den Bakker MA, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 2009; 8:1278-94.
3. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000; 60:4026-9.
4. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997; 57:1244-9.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
6. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, Nguyen C, et al. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 2003; 3:13.
7. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 2009; 106:14536-41.
8. Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 2007; 138:37-44. (Pubitemid 46227456)
9. Harris TE, Lawrence JC Jr. TOR signaling. Sci STKE 2003; 2003:15.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501. (Pubitemid 37328931)
11. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004; 6:219-24.
12. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86:540-5.
13. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10:8059-67.
14. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68:826-33. (Pubitemid 351206760)
15. Thomas J, Hanby A, Pinder S, Ellis I, Macartney J, Clements K, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J 2008; 14:33-8.
16. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456:663-6.
17. Graham ML, 2nd, Smith JA, Jewett PB, Horwitz KB. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 1992; 52:593-602.
18. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997; 57:1597-604. (Pubitemid 27175581)
19. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101:9393-8.
20. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by upregulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4:1533-40. (Pubitemid 41556435)
21. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8. (Pubitemid 41161231)
22. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8. (Pubitemid 43259931)
23. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003; 22:7989-97. (Pubitemid 37179944)
24. Silberstein GB, Dressler GR, Van Horn K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 2002; 21:1009-16. (Pubitemid 34174513)
25. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004; 3:379-98. (Pubitemid 38702091)
26. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009; 11:11.
27. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22.
28. Basse B, Baguley BC, Marshall ES, Joseph WR, van Brunt B, Wake G, Wall DJ. Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. J Math Biol 2004; 49:329-57. (Pubitemid 40171917)